Top

Breast Cancer Research and Treatment

Published in:

01-09-2010 | Letter to the Editor

Expression of the stem cell marker ALDH1 in the normal breast of BRCA1 mutation carriers

Authors: Marise R. Heerma van Voss, Petra van der Groep, Joost Bart, Elsken van der Wall, Paul J. van Diest

Published in: Breast Cancer Research and Treatment | Issue 2/2010

Excerpt

To the Editor, …

Kubista M, Rosner M, Kubista E, Bernaschek G, Hengstschlager M (2002) Brca1 regulates in vitro differentiation of mammary epithelial cells. Oncogene 21:4747–4756CrossRefPubMed

Furuta S, Jiang X, Gu B, Cheng E, Chen PL, Lee WH (2005) Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proc Natl Acad Sci USA 102:9176–9181CrossRefPubMed

Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, Merajver SD et al (2008) BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA 105:1680–1685

Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH et al (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15:907–913

Vasiliou V, Pappa A, Petersen DR (2000) Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism. Chem Biol Interact 129:1–19CrossRefPubMed

Ginestier C, Wicinski J, Cervera N, Monville F, Finetti P, Bertucci F et al (2009) Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle 8:3297–3302

Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K (2010) Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 16:876–887CrossRefPubMed

Burga LN, Tung NM, Troyan SL, Bostina M, Konstantinopoulos PA, Fountzilas H et al (2009) Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. Cancer Res 69:1273–1278

Title: Expression of the stem cell marker ALDH1 in the normal breast of BRCA1 mutation carriers
Authors: Marise R. Heerma van Voss
Petra van der Groep
Joost Bart
Elsken van der Wall
Paul J. van Diest
Publication date: 01-09-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-1005-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2010

Corticosteroid treatment and timing of surgery in idiopathic granulomatous mastitis confusing with breast carcinoma

Past recreational physical activity, body size, and all-cause mortality following breast cancer diagnosis: results from the breast cancer family registry

Extremely low-frequency electromagnetic fields exposure and female breast cancer risk: a meta-analysis based on 24,338 cases and 60,628 controls

Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice

Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival

Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ

Keynote webinar | Spotlight on antibody–drug conjugates in cancer